B
Bicycle Therapeutics Ltd (BCYC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$3.20
+0.02 (+0.63%)
Market Cap: $222.90M
Last updated: Nov 17, 2026 at 4:15 PM ET
Bicycle Therapeutics Ltd (BCYC) Valuation Multiples
Bicycle Therapeutics (BCYC) trades at 2.7x sales and 0.4x book value. Its P/S of 2.7x is below its 5-year median of 25.2x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | N/A |
| Price to sales | 2.7x |
| Price to book | 0.4x |
| PEG | N/A |
| FCF yield | -78.9% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 2.7x | 25.2x | N/A |
| P/B | 0.4x | 1.6x | N/A |
Valuation History
Over the 7 year ends shown, its P/S ranged from 6.8x in 2025 to 132.3x in 2021. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $7.08 | 6.8x | 0.8x |
| 2024 | $14.00 | 19.1x | 1.2x |
| 2023 | $18.08 | 22.6x | 2.1x |
| 2022 | $29.60 | 60.7x | 3.2x |
| 2021 | $60.87 | 132.3x | 5.1x |
| 2020 | $17.95 | 33.9x | 4.0x |
| 2019 | $9.43 | 10.5x | 1.8x |
Frequently Asked Questions About BCYC
What is BCYC's price to sales ratio?
Bicycle Therapeutics has a price to sales ratio of 2.7x.
BCYC pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors